Combining Lysosomal Enzyme Inhibition with KRAS-MAPK Pathway Targeting Shows Promise for Pancreatic Cancer Treatment
Recent research from the University of Michigan has demonstrated that a dual therapeutic approach targeting both lysosomal enzymes and the KRAS-MAPK signaling pathway can effectively eradicate pancreatic tumors in preclinical models. Pancreatic ductal adenocarcinoma (PDAC), the most common and deadly form of pancreatic cancer, remains difficult to treat due to its complex tumor microenvironment, characterized by a high proportion of non-cancerous cells that support tumor survival.
The study highlights the role of lysosomes—cellular organelles responsible for degrading and recycling cellular waste—in supporting malignant cell survival despite poor nutrient supply caused by abnormal blood vessels. Researchers focused on PIKfyve, an enzyme involved in lysosomal function, which has previously been targeted in other cancer types. Genetic deletion or pharmacological inhibition of PIKfyve, using agents like apilimod and ESK981, significantly reduced tumor growth in mouse models.
Further investigations revealed that inhibiting PIKfyve disrupted lysosomal fatty acid recycling, compelling cancer cells to increase their own fat synthesis via the KRAS-MAPK pathway—an important driver of pancreatic cancer. While targeting KRAS itself has been a significant step forward, cancer cells often develop resistance to these inhibitors, emphasizing the need for combination therapies.
By simultaneously targeting PIKfyve and KRAS-driven metabolic processes, the researchers achieved complete tumor remission in several preclinical models. This approach rewires lipid metabolism within cancer cells and enhances the efficacy of existing KRAS inhibitors. The findings suggest that integrating lysosomal enzyme inhibition with pathway-specific treatments could offer a new, more effective strategy for managing pancreatic cancer.
The research team is optimistic about translating these findings into clinical trials and is exploring ways to harness the immune response to eliminate residual tumor cells, aiming to overcome resistance and improve patient outcomes. This innovative combination approach underscores the potential of targeting tumor metabolism alongside genetic pathways to fight this formidable disease.
Source: MedicalXpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Gut Microbe Balance May Be Crucial in Early-Onset Colorectal Cancer, Mouse Study Finds
Research reveals that the balance of gut microbes and their metabolites may influence the risk of developing early-onset colorectal cancer. A mouse study highlights potential microbiome-targeted interventions for prevention.
Pediatricians' Group Recommends COVID-19 Vaccines for Young Children, Diverging from CDC Guidelines
The American Academy of Pediatrics has issued new COVID-19 vaccine recommendations for children, diverging from CDC guidance. The new guidelines advocate for broader vaccination coverage, especially for high-risk kids, amid rising cases and policy shifts, emphasizing individual choice and updated safety data.
Tennessee Lowers the Standards for Ballad Health's Hospital Monopoly Amidst Concerns
Tennessee has lowered the standards for Ballad Health's hospital monopoly, allowing continued operation despite poor performance scores and limiting public access to performance data. The change raises concerns about transparency and healthcare quality.
Reevaluating the Role of Anticoagulation in Patients with Device-Detected Atrial Fibrillation
New findings from the NOAH—AFNET 6 trial suggest that anticoagulation offers minimal benefit and increased risks for patients with device-detected atrial fibrillation, emphasizing personalized treatment strategies.